Search hospitals > Nebraska > Omaha
Oncology Hematology West PC
Claim this profileOmaha, Nebraska 68130
Global Leader in Cancer
Global Leader in Lung Cancer
Conducts research for Breast Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Squamous Cell Carcinoma
94 reported clinical trials
11 medical researchers
Summary
Oncology Hematology West PC is a medical facility located in Omaha, Nebraska. This center is recognized for care of Cancer, Lung Cancer, Breast Cancer, Non-Small Cell Lung Cancer, Squamous Cell Carcinoma and other specialties. Oncology Hematology West PC is involved with conducting 94 clinical trials across 264 conditions. There are 11 research doctors associated with this hospital, such as Ralph Hauke, MD, Brent Tierney, MD, Timothy Huyck, and Robert M. Langdon.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage I
2Lung Cancer
Global LeaderStage IV
Stage III
Stage II
Top PIs
Ralph Hauke, MDNebraska Cancer Specialists5 years of reported clinical research
Expert in Cancer
Studies Prostate Cancer
35 reported clinical trials
73 drugs studied
Brent Tierney, MDNebraska Methodist Hospital1 year of reported clinical research
Expert in Ovarian Cancer
Studies Cancer
22 reported clinical trials
40 drugs studied
Timothy HuyckNebraska Methodist Hospital6 years of reported clinical research
Studies Colorectal Cancer
Studies Adenocarcinoma
15 reported clinical trials
31 drugs studied
Robert M. LangdonNebraska Methodist Hospital10 years of reported clinical research
Studies Lung Cancer
Studies Non-Small Cell Lung Cancer
13 reported clinical trials
42 drugs studied
Clinical Trials running at Oncology Hematology West PC
Breast Cancer
Non-Small Cell Lung Cancer
Squamous Cell Carcinoma
Lung Cancer
Cancer
Bladder Carcinoma
Renal Cell Carcinoma
Bladder Cancer
Pancreatic Cancer
Ovarian Cancer
Pembrolizumab
for Triple-Negative Breast Cancer
The phase III trial compares the effect of pembrolizumab to observation for the treatment of patients with early-stage triple-negative breast cancer who achieved a pathologic complete response after preoperative chemotherapy in combination with pembrolizumab. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial may help researchers determine if observation will result in the same risk of cancer coming back as pembrolizumab after surgery in triple-negative breast cancer patients who achieve pathologic complete response after preoperative chemotherapy with pembrolizumab.
Recruiting2 awards Phase 319 criteria
T-DM1 + Tucatinib
for Breast Cancer
This phase III trial studies how well trastuzumab emtansine (T-DM1) and tucatinib work in preventing breast cancer from coming back (relapsing) in patients with high risk, HER2 positive breast cancer. T-DM1 is a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug, called DM1. Trastuzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as HER2 receptors, and delivers DM1 to kill them. Tucatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving T-DM1 and tucatinib may work better in preventing breast cancer from relapsing in patients with HER2 positive breast cancer compared to T-DM1 alone.
Recruiting1 award Phase 313 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Oncology Hematology West PC?
Oncology Hematology West PC is a medical facility located in Omaha, Nebraska. This center is recognized for care of Cancer, Lung Cancer, Breast Cancer, Non-Small Cell Lung Cancer, Squamous Cell Carcinoma and other specialties. Oncology Hematology West PC is involved with conducting 94 clinical trials across 264 conditions. There are 11 research doctors associated with this hospital, such as Ralph Hauke, MD, Brent Tierney, MD, Timothy Huyck, and Robert M. Langdon.